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Epidermal growth factor receptor inhibition attenuates early
kidney enlargement in experimental diabetes.
Background. Renal enlargement is an early feature of both
human and experimental diabetes. Although the precise mecha-
nisms underlying its development are incompletely understood,
locally active growth factors have been suggested to have a key
role. Having previously documented increased expression of
the proproliferative and antiapoptotic growth factor, epidermal
growth factor (EGF), in early diabetes-related kidney growth,
the present study sought to evaluate its pathogenetic role by
blocking its action with a specific inhibitor.
Methods. Sprague-Dawley rats were randomized to receive
streptozotocin (diabetic) or buffer (control) and then further
randomized to receive either vehicle or the inhibitor of the EGF
receptor tyrosine kinase, PKI 166 (100 mg/kg/day) for 2 days and
3 weeks following streptozotocin administration.
Results. Experimental diabetes was associated with an in-
crease in kidney weight and tubular epithelial cell proliferation
as identified by increased expression of proliferating cell nuclear
antigen (PCNA) and 5-bromo-2′-deoxyuridine (BrdU) incor-
poration. PKI 166 resulted in a 30% reduction in kidney weight
in diabetic rats (P < 0.01) and reduced tubular epithelial cell
proliferation (P < 0.01). In addition, EGF receptor inhibition
also led to a 40% increase in tubular epithelial cell apoptosis
at 3 weeks (P < 0.01). Diabetes-associated glomerular enlarge-
ment was similarly attenuated by PKI 166, although glomerular
hyperfiltration was unaffected.
Conclusion. These findings suggest that the EGF-EGF re-
ceptor (EGFR) axis has a significant role in the development
of early diabetes-related kidney growth. The impact of EGFR
inhibition on the later development of renal dysfunction, how-
ever, remains to be determined.
Renal enlargement is a characteristic feature of human
[1] and experimental diabetes [2] that may be predictive
of subsequent nephropathy in patients with both type 1
[3] and type 2 diabetes [4]. It is present at diagnosis in
patients with type 1 diabetes and is found soon after in-
duction of experimental diabetes in animal models [1].
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For instance, in the streptozotocin rat, increased kidney
weight is detectable 36 hours following the induction of
diabetes and increases by approximately 20% within 1
week, doubling in size by 6 weeks [5]. Both hyperplasia
and hypertrophy contribute to kidney enlargement in di-
abetes, although cell proliferation predominates in renal
tubules, while changes in the glomerulus are mostly the
result of hypertrophy [6].
The mechanisms responsible for diabetes-related renal
growth remain incompletely understood, although locally
active growth factors have been repeatedly implicated.
Indeed, a large number of these factors have been found
to be up-regulated in early diabetes, including epidermal
growth factor (EGF) [7, 8]. The mammalian kidney is a
major site of synthesis of this prototypic growth factor [9],
which acts locally to both stimulate tubular cell prolifera-
tion [10, 11] and inhibit apoptosis [12, 13]. However, given
the myriad of growth factors associated with diabetes,
their frequent overlapping actions and redundancies, es-
tablishing the role of an individual factor requires the
demonstration that its blockade leads to a demonstrable
effect in the disease process [14]. The present study thus
took advantage of the recent development of a specific
inhibitor of the EGF receptor (EGFR) tyrosine kinase,
PKI 166 [15, 16], determined its effectiveness in cultured
rat kidney cells and then used it to examine the role of
the EGF system in the development of diabetes-related
kidney growth, focusing on aspects related to the known
actions of EGF [10, 12]. Renal growth was therefore ex-
amined at two time points. First, kidneys were studied
at 2 days following the induction of experimental dia-
betes, when cell proliferation is at its maximum [6] and
at 3 weeks by which time a substantial increase in kidney
weight is evident [2].
METHODS
Inhibition of EGFR phosphorylation with PKI 166 in rat
kidney cells
The effect of PKI 166 on EGFR phosphorylation in
rat kidney cells was examined using a normal rat kidney
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epithelial cells line (NRK-52E, kind gift of Dr Vicki
Levidiotis, Austin Health, Melbourne, Australia) with the
additions of EGF and PKI 166 as previously reported
in other cell culture studies [16, 17]. In brief, cells were
grown in Dulbecco’s modified Eagle’s media (DMEM),
supplemented with 10% fetal calf serum (FCS), 4 mmol/L
L-glutamine and a penicillin-streptomycin mixture. To
evaluate the effect of PKI 166, cells in 6-well plates
were rendered quiescent by serum removal 24 hours
prior to the experimental procedure. Serum-starved cells
were treated with 10 ng/mL EGF 10 with or without
PKI 166 (4 lmol/L) for 30 minutes, as previously de-
scribed in other cell systems [16]. Cells were then washed
with phosphate-buffered saline (PBS) and 200 lL ra-
dioimmunoprecipitation assay (RIPA) buffer [50 mmol/L
Tris, pH 7.5; 150 mmol/L NaCl; 1 mmol/L ethylene-
diaminetetraacetic acid (EDTA); 1 mmol/L egtazic
acid (EGTA); 0.5% Triton-X; 0.5% NP-40; 1 mmol/L
Na3VO4; 50 mmol/L NaF; 25 mmol/L b-glycerphosphate;
10 mmol/L sodium-pyrophosphate; 10 lL/mL aprotinin;
20 lL/mL leupeptin; and 1 mmol/L phenylmethylsulfonyl
fluoride (PMSF)] was added to each well. Cells were
lysed on ice by repeated passage through a 21 gauge
needle and centrifuge at 13,000g for 10 minutes. The su-
pernatant was stored at −70◦C for subsequent Western
blots analysis. Protein concentrations were assessed using
the Bio-Rad DC Protein Assay (Bio-Rad, Hercules, CA,
USA). Twenty micrograms of protein for each sample
was added to 2× sample buffer [125 mmol/L Tris HCl,
pH 6.8; 4% sodium dodecyl sulfate (SDS); 20% glyc-
erol; 10% b-mercaptoethanol, and 0.004% bromophenol
blue), boiled, separated on a 7.5% SDS-polyacrylamide
gel electrophoresis (PAGE) and transferred to polyvinyli-
dine difluoride (PVDF) membrane (Roche Diagnostics,
Mannheim, Germany). Following transfer, membranes
were incubated in Ponceau S stain (Sigma Chemical Co.,
St. Louis, MO, USA) to ensure equal loading of pro-
tein. Membranes were treated with 5% nonfat milk in
Tris-buffered saline (TBS) with 0.1% Tween (TBS-T) for
1 hour and probed with either rabbit polyclonal anti-
EGFR (1:500) (Cell Signaling Technology, Beverly, MA,
USA), or antibody specific for phosphorylated EGFR
(1:1000) (Tyr 1068) (Cell Signaling Technology) with 5%
bovine serum albumin (BSA) in TBS-T overnight at
4◦C. Membranes were washed with TBS-T and incubated
with horseradish peroxidase–conjugated antirabbit IgG
(1:5000) (Cell Signaling Technology) in 5% nonfat milk
in TBS-T. Protein bands were visualized by the Supersig-
nal West Femto Maximum Sensitivity Substrate (Pierce
Biotechnology, Inc., Rockford, IL, USA). Densitomet-
ric quanatitation of Western blots was performed using
MCID M2 version 3 (Imaging Research Inc., St Cather-
ine’s, Ontario, Canada). Results are the mean of at least
three experiments.
Animals
Eight- to ten-week-old male Sprague-Dawley rats,
weighing 288 ± 5 g were randomized to receive either
50 mg/kg of streptozotocin (STZ) (Sigma Chemical Co.)
diluted in 0.1 mol/L citrate buffer, pH 4.5 (diabetic) or
citrate buffer alone (control) by tail vein injection fol-
lowing an overnight fast. Diabetic and control rats were
further randomized to receive the selective EGFR tyro-
sine kinase inhibitor, PKI 166 [4-(R)-phenethylamino-6-
(hydroxyl)phenyl-7H-pyrrolo [2.3.d].pyrimidine] (a gift
of Peter Traxler, Novartis, Basel, Switzerland) dissolved
in 30% polyethylene glycol 300 (PEG 300) (Sigma Chem-
ical Co.) and 1-methyl-2-pyrrolidinone (NMP) (Sigma
Chemical Co.) or vehicle alone (PEG 300 and NMP), for
2 days (N = 12 per group) or 3 weeks (N = 8 per group)
post-STZ. Oral administration of PKI 166 was given by
daily gavage at a dose of 100 mg/kg [18]. Rats were housed
in a temperature (22 ± 1◦C) and light (12-hour light
day cycle) controlled room with ad libitum access to tap
water and standard rat chow. At the end of the experi-
mental period, body weight was recorded and blood glu-
cose and glomerular filtration rate (GFR) were measured
by Advantage Blood Glucose Monitor (Roche Diagnos-
tics, NSW, Sydney, Australia) and by single-shot 99m-
technetium diethylenetriamine pentaacetic acid (Tc99m-
DTPA) clearance, respectively [13]. Blood pressure was
determined in conscious rats by tail cuff plethysmogra-
phy, as previously described [19]. For the 2-day study,
animals received a single intraperitoneal injection of
50 mg/kg 5-bromo-2′-deoxyuridine (BrdU) (10 mg/mL)
(Sigma Chemical Co.) 2 hours prior to sacrifice, in order
to label cells in the DNA synthetic (S) phase of the cell
cycle. Experimental procedures adhered to the guidelines
of the National Health and Medical Research Council of
Australia’s Code of the Care and Use of Animals for sci-
entific purposes and approved by St. Vincent’s Hospital
Animal Ethics Committee, Melbourne, Australia.
Tissue collection
Rats were anaesthetized with Nembutal (pentobarbi-
tone sodium, 60 mg/kg body weight intraperitoneally)
(Boehringer-Ingelheim, Australia). The left renal artery
was then clamped and the kidneys were removed, decap-
sulated, weighed, and snap frozen in liquid nitrogen. The
abdominal aorta was cannulated with a 19 gauge needle.
Perfusion-exsanguination commenced at 180 to 220 mm
Hg via the abdominal aorta with 0.1 mol/L PBS, pH 7.4,
to remove circulating blood and the inferior vena cava
adjacent to the renal vein was simultaneously severed al-
lowing free flow of the perfusate. After clearance of circu-
lating blood, 10% neutral-buffered formalin (NBF) was
perfused to fix tissues. The right kidney was removed,
decapsulated, sliced transversely, routinely processed,
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embedded in paraffin, and sectioned for light microscopic
examinations.
Glomerular volume
Four micrometer sections were stained with haema-
toxylin and eosin. Fifty random glomeruli per section
were captured using Fujix HC-2000 digital camera and
glomerular cross-sectional area (GA) was measured us-
ing the Analytical Imaging Station (AIS) software. The
mean glomerular volume (GV) was then calculated as:
GV = (b/k)(GA)3/2
where b = 1.38 pertains to the sphere, and k = 1.10 is the
distribution coefficient [20].
PCNA immunohistochemistry
Four micron sections were deparaffinized with histo-
lene, rehydrated with graded ethanol, and treated with
3% H2O2. Antigen retrieval technique was performed by
placing sections into boiling 0.01 Mmol/L citrate buffer,
pH 6, for 5 minutes [21]. Once sections were cooled and
washed in PBS, they were treated with 5% goat serum
for 30 minutes followed by incubation with PCNA (1:50)
(Dako, Carpenteria, CA, USA) for 18 hours at 4◦C. Sec-
tions were washed in PBS, treated with biotinylated goat
antimouse antibody for 45 minutes, followed by incu-
bation with avidin-biotin peroxidase complex (Vector,
Burlingame, CA, USA) for 40 minutes. Diaminobenzi-
dene (DAB) (Dako) was used as a chromogen and sec-
tions were counterstained with eosin. Negative control
included omitting the primary antibody and replacing it
with 5% goat serum. Sections of rat testis were used as a
positive control.
The extent of PCNA staining was examined in the im-
ages of 15 randomly selected fields (×200 magnification)
per section that were captured and digitized using a Fujix
HC-2000 digital camera. The number of positively stained
nuclei (brown) was then quantified.
BrdU incorporation
Incorporation of BrdU was assessed as previously de-
scribed [22]. In brief, 4 l sections were deparaffinized
with histolene and rehydrated with graded ethanol, fol-
lowed by treatment with 3% H2O2 to remove en-
dogenous peroxidase. Kidney sections underwent DNA
denaturation by incubation with 2 mol/L HCl for 20 min-
utes at 37◦C and enzymatic pretreatment by treating sec-
tions with 0.1% trypsin for a further 15 minutes at 37◦C.
Sections were then incubated with 5% goat serum for
20 minutes at 37◦C, followed by the addition of the mon-
oclonal anti-BrdU antibody (1:1000) (Sigma Chemical
Co.) for 2 hours at 37◦C. Sections were washed in PBS
(3× 5 minutes) and incubated with biotinylated goat an-
timouse immunoglobin (Dako) for 45 minutes at room
temperature. After rinsing with PBS (3× 5 minutes) sec-
tions were incubated with an avidin-biotin peroxidase
complex (Vector) for 30 minutes at room temperature.
Peroxidase conjugates were localized using DAB as a
chromogen and counterstained with eosin. Sections in-
cubated with 5% goat serum instead of the primary anti-
body served as a negative control, whereas intestine from
a BrdU-injected rat served as a positive control. The ex-
tent of BrdU immunolabeling was assessed as described
for PCNA.
Terminal deoxyuridine triphosphate (dUTP)
nick-end labeling (TUNEL)
To examine apoptosis in the kidneys the TUNEL
method was followed [23]. Briefly, sections were de-
paraffinized and rehydrated. Permeabilization and re-
moval of endogenous peroxidase was carried out by
treating sections with 20 lg/mL proteinase K (Roche
Diagnostics, Mannheim, Germany) for 30 minutes and
3% H2O2 for 5 minutes, respectively. After sections
were washed in H2O (2× 5 minutes), they were treated
with terminal deoxynucleotidyl transferase (TdT) buffer
(Roche Diagnostics) for 20 minutes to allow for equili-
bration before being treated with TdT enzyme (10 U)
(Roche Diagnostics) and biotinylated dUTP (1 nmol)
Roche Diagnostics) for 60 minutes at 37◦C in a dark
humidified chamber. The reaction was stopped with
TB buffer (300 mmol/L NaCl and 30 mmol/L sodium
citrate) for 15 minutes and washed with PBS (2× 5
minutes). Sections were then treated with streptavidin-
conjugated horseradish peroxidase (1:300) (Dako) for
30 minutes at 37◦C, washed, incubated with DAB, and
counterstained with eosin. Negative control was gener-
ated by not treating the section with TdT enzyme, while
the positive control was treated with 1 lg/lL DNase
I (Promega) in 1 mmol/L MgSO4/PBS for 20 minutes
prior to incubation with 3% H2O2. The extent of TUNEL
staining was assessed as described for PCNA.
Active caspase-3 immunohistochemistry
Activated caspase-3 was assessed by quantifying the
expression of its cleaved (active) form in tissue sections.
In brief, 4 l sections were deparaffinized with histolene
and rehydrated with graded ethanol. Permeabilization
was achieved by treating with 20 lg/mL proteinase K
(Roche Diagnostics) for 20 minutes followed by three
5-minute washes. Three percent H2O2 was added to slides
for 15 minutes for the removal of endogenous peroxi-
dase. Sections were washed in PBS, and treated with 5%
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Fig. 1. Western blots of epidermal growth factor receptor (EGFr) and
phosphorylated EGFr (p-EGFr) with and without PKI 166 in NRK52E
cells. NRK52E cells treated with epidermal growth factor (EGF) for
different time points and with or without the addition of PKI 166 possess
the EGF receptor. The absence of EGF or the addition of PKI 166 to
cells resulted in inhibiting EGF receptor phosphorylation at tyrosine
1068. The graph represents the semiquantification of the Western blots,
demonstrating that the ratio of p-EGFr:EGFr was reduced with PKI
166. A431 cells treated with EGF served as a positive control.
goat serum for 40 minutes followed by an overnight incu-
bation at 4◦C with antiactive caspase 3 antibody (1:400)
(Promega). Sections were left at room temperature for
30 minutes, washed in PBS (3× 5 minutes), and treated
with 3% H2O2 for 10 minutes. Following another
wash with PBS, slides were treated with horseradish
peroxidase-labeled polymer goat antirabbit IgG (Dako
Envision System, Dako) for 1 hour at room temperature.
DAB was used as a chromagen and slides were dehy-
drated with ethanol and histolene. A section of small in-
testine was used as a positive control. Negative controls
included omitting the primary antibody and substituting
it with 5% goat serum. The extent of anticaspase-3 stain-
ing was examined in the images of five randomly selected
fields (×200 magnification) per section that were cap-
tured and digitized using a Fujix HC-2000 digital camera,
as described above for PCNA.
Table 1. Body weight, blood glucose, and glomerular filtration rate
(GFR) at 2 days and 3 weeks
Blood glucose
Group Number Body weight g mmol/L
2 days
Control + vehicle 12 302 ± 2.7 6.9 ± 0.13
Control + PKI 166 12 301 ± 2.3 6.9 ± 0.23
Diabetic + vehicle 12 280 ± 3.4a 24.2 ± 0.81b
Diabetic + PKI 166 12 270 ± 2.7a 22.4 ± 0.56b
3 weeks
Control + vehicle 10 427 ± 8.5 6.4 ± 0.16
Control + PKI 166 8 399 ± 8.4 6.3 ± 0.27
Diabetic + vehicle 10 319 ± 15.3b 28.5 ± 1.12b
Diabetic + PKI 166 8 306 ± 11.4b 27.0 ± 0.85b
Data expressed as mean ± SEM.
aP < 0.05; and bP < 0.001 versus control.
Statistics
Results are expressed as mean ± SEM. Statistical
significance was evaluated with analysis of variance
(ANOVA) with a least significance difference post hoc
comparison using the SPSS software package (SPSS, Inc.,
Chicago, IL, USA). A P value < 0.05 was considered sta-
tistically significant.
RESULTS
Effect of PKI 166 on rat renal epithelial cells in vitro
The EGFR was present in NRK52E (rat renal epithe-
lial cell line) as demonstrated by the Western blot (Fig. 1).
Cells exposed to 10 ng/mL EGF lead to an increase in
EGFR phosphorylation (Fig. 1). Treatment with PKI 166
abolished EGFR phosphorylation, even in the presence
of EGF (Fig. 1).
Body weight, blood glucose, blood pressure, and kidney
weight
Rats that had received STZ were all diabetic and had a
lower body weight than control rats (Table 1). Diabetes
was associated with increased kidney weight compared
with controls at week 3 (Fig. 2A) (P < 0.001). However,
in diabetic rats treated with PKI 166 kidney weight was re-
duced when compared with vehicle-treated diabetic rats
(Fig. 2A) (P < 0.01). This reduction in kidney size with
PKI 166 treatment was also observed when kidney weight
was expressed relative to body weight (Fig. 2B) (P <
0.01). Treatment with PKI 166 had no effect on plasma
glucose, body weight in either diabetic or nondiabetic
animals. Similarly, blood pressure was also unaffected by
PKI 166 (control 129 ± 3.9 mm Hg; control + PKI 166
133 ± 3.5 mm Hg; diabetes 139 ± 7.5 mm Hg; diabetes +
PKI 166 139 ± 2.6 mm Hg).
Proliferation analysis by PCNA and BrdU
immunohistochemistry
At day 2, diabetic rats showed a twofold increase in
the number of PCNA-positive tubular epithelial cells,
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Fig. 2. Effects of diabetes and PKI 166 treatment on kidney weight in
control and diabetic rats. (A) Diabetic rats had a significantly greater
kidney weight compared with control rats at week 3. Treatment with
PKI 166 in diabetic rats was associated with decreased kidney weight
compared with untreated diabetic animals. (B) These changes in kidney
weight were also observed when expressed relative to body weight. Data
expressed as mean ± SEM. ∗P < 0.001 versus control; †P < 0.01 versus
untreated diabetic rats.
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Fig. 3. Expression of proliferating cell nuclear antigen (PCNA) (A)
and 5-bromo-2′-deoxyuridine (BrdU) (B) in control and diabetic rats at
2 days. Untreated diabetic rats showed an increased number of PCNA-
positive tubular cells compared with control animals as shown. PKI 166
reduced the number of PCNA-positive cells in diabetic rats compared
with untreated diabetic animals (A). Similar results were observed with
BrdU immunohistochemistry. Data expressed as mean ± SEM. †P <
0.05; ‡P < 0.01 versus untreated diabetic rats.
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Fig. 5. Apoptosis as shown with terminal deoxyuridine triphosphate
(dUTP) nick-end labeling (TUNEL) (A) and active caspase 3 labeling
(B) in control and diabetic rats, treated with and without PKI 166 at
3 weeks. Treatment with PKI 166 for 3 weeks (A) in the diabetic rats
was accompanied by increased apoptosis compared with vehicle treated
diabetic rats. Active Caspase-3 [proportional area (%) positive] was also
increased with PKI 166 treatment for 3 weeks in diabetic rats (B). Data
expressed as mean ± SEM. ∗P < 0.01 versus untreated diabetic rats.
indicative of enhanced cell proliferation (Figs. 3A and
4) (P < 0.01). Treatment with PKI 166 attenuated the
number of PCNA-positive cells to levels similar to those
seen in control animals (Fig. 3A) (P < 0.01). Similar
findings were noted for BrdU incorporation at 2 days
(Fig. 4B) (P < 0.01).
Apoptosis
Two days following STZ administration, the number
of TUNEL-positive nuclei was similar in control and di-
abetic animals, treated with or without PKI 166 (data not
shown). However, at 3 weeks, diabetic rat treatment with
PKI 166 daily showed a 40% increase in tubular apopto-
sis, compared with untreated diabetic rats (Figs. 5A and
6) (P < 0.01). Cleaved caspase-3 showed similar findings
with increased immunostaining in the proximal tubules
of diabetic rats treated with PKI 166 compared with their
untreated counterparts (Figs. 5B and 7) (P < 0.05).
GFR and GV
At 3 weeks, GV was 22% greater in diabetic rats com-
pared with controls animals (Fig. 8) (P < 0.05). Treatment
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Fig. 4. Representative photomicrograph of proliferating cell nuclear antigen (PCNA) immunostaining in control (A and C) and diabetic rats (B
and D), treated with (C and D) or without (A and B) PKI 166. Diabetic rats displayed abundant PCNA-positive nuclei in renal tubules, compared
with control and PKI 166-treated diabetic rats. Sections counterstained with eosin (magnification ×280).
Fig. 6. Representative terminal deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) for 3-week study. No difference in the number
of TUNEL-positive tubular cells was observed between diabetic rats (B and D) and their respective controls (A and C). TUNEL labeling was
increased with PKI 166 in the diabetic rats (D) compared to vehicle treated diabetic rats. (B) Sections counterstained with eosin (magnification
×280).
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Fig. 7. Active caspase-3 immunohistochemistry. Representative photomicrographs of active caspase-3 immunostaining in kidney sections from
control (A), diabetic (B), control + PKI 166 (C), and diabetic + PKI 166 (D) at 3 weeks, showing greater immunolabeling in diabetic animals
treated with PKI 166 in comparison to other groups. Sections counterstained with hematoxylin (magnification ×280).
with PKI 166 resulted in a modest but significant reduc-
tion in glomerular enlargement (Fig. 8) (P < 0.05). GFR
was increased by 46% at 3 weeks in diabetic rats (P <
0.01), but was unaffected by PKI 166 (Fig. 9).
DISCUSSION
The present study demonstrates several findings in re-
lation to the role of the EGF-EGFR system in the de-
velopment of renal enlargement in diabetes. Blockade of
EGFR activity with PKI 166 led to a reduction in kidney
growth in association with an early diminution in tubular
cell proliferation. Later, when increased proliferation was
no longer apparent, EGFR blockade led to an increase
in tubular epithelial apoptosis. In addition, glomerular
hypertrophy was also decreased with PKI 166, although
glomerular hyperfiltration was unaffected. The in vitro
studies demonstrate that PKI 166 is a potent inhibitor of
EGFR tyrosine kinase phosphorylation in rat renal ep-
ithelial cells.
While the observation that diabetes is associated with
bilateral renal enlargement was made in 1841 [24], the
mechanisms underlying its development have only re-
cently begun to be unraveled, with growth factors sug-
gested to have a key role [25]. Kidney growth in diabetes
includes cell hyperplasia [6] as well as hypertrophy [26]
and the accumulation of extracellular matrix material
[27]. While the role of transforming growth factor-b
(TGF-b) in the development of hypertrophy and ma-
trix formation has been previously explored [28], this
growth factor is predominantly antiproliferative and thus
unlikely to account for the cell hyperplasia that occurs
soon after the induction of experimental diabetes. By con-
trast, EGF is a potent proproliferative and antiapoptotic
growth factor [29] that is also overexpressed in the dia-
betic kidney [7].
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Fig. 8. Effects of diabetes and PKI 166 treatment on glomerular vol-
ume at 3 weeks. Diabetic rats had significantly larger glomerular vol-
umes compared with control rats at and week 3. At week 3, treatment
with PKI 166 in diabetic rats reduced glomerular volume compared with
untreated diabetic animals. Data expressed as mean ± SEM. ∗P < 0.01
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Fig. 9. Effects of diabetes and PKI 166 treatment on glomerular filtra-
tion rate (GFR) at 3 weeks. Diabetic rats had a significantly increased
GFR compared to control animals. PKI 166 was without affect on GFR
in either control or diabetic rats. Data expressed as mean ± SEM. ∗P
< 0.001 versus control.
Following the induction of STZ diabetes in the rat, a
burst of increased thymidine incorporation is observed,
peaking at 48 hours and with an estimated 50% increase
in cell number within the first week [6]. Similarly, in the
present experiment, markers of cell proliferation were
increased in the tubular epithelium at 2 days after STZ
administration, with a twofold elevation of PCNA la-
beling and BrdU incorporation. Without affecting blood
glucose, treatment with PKI 166 reduced the number of
PCNA and BrdU-positive nuclei, suggesting that activa-
tion of the EGFR plays an important role in this early
hyperplastic phase of kidney growth in diabetes. These
findings in a diabetic model complement those found in
the nondiabetic renal enlargement that occurs following
unilateral nephrectomy in which anti-EGF antibody was
found to reduce the associated renal cell hyperplasia [30].
After 3 weeks of STZ diabetes, cell proliferation was
no longer different between control, diabetic, and PKI
166–treated diabetic animals. However, cell number re-
flects the balance between cell proliferation and cell loss.
We therefore sought to determine whether differences
in the rates of apoptosis might also contribute to the
previously described increased cell number in diabetic
nephromegaly [6]. The present studies showed that while
there was no difference in tubular cell apoptosis between
control and untreated diabetic animals, PKI administra-
tion to diabetic animals led to an increase in apoptosis,
as indicated by TUNEL and active caspase-3 labeling, a
key “execution” enzyme in the apoptotic pathway [31].
These findings are consistent with the in vitro findings
in the kidney and elsewhere indicating that activation of
the EGFR protects against apoptosis induced by a range
of stimuli [12, 32–35]. However, whether the increase in
apoptosis induced by EGFR kinase inhibition ultimately
leads to beneficial changes in tubular structure in long-
term diabetes remains to be determined.
Glomerular enlargement is a prominent feature of di-
abetic nephromegaly. However, in contrast to the renal
tubule, changes in the glomerulus are mostly a conse-
quence of hypertrophy rather than hyperplasia [6]. As ex-
pected, in the present study, evidence of cell proliferation
was absent in glomerular cells. Nevertheless, treatment
with PKI 166 still led to the attenuation of diabetes-
induced glomerular enlargement. The mechanisms
underlying the antitrophic effect of PKI 166 in the
glomerulus are uncertain. Indeed, the interrelationship
between glomerular and tubular growth in early diabetes
remains incompletely understood with a range of site-
specific changes in growth factor expression within the
diabetic nephron. For instance, although EGF is a po-
tent proproliferative growth factor its mitogenic action is
curtailed in the presence of TGF-b . This latter, antipro-
liferative growth factor, substantially overexpressed in
glomeruli early in the course of diabetes-related kidney
growth [36], blocks cell cycle progression at G1/S transi-
tion and converts EGF-induced hyperplasia into hyper-
trophy [37].
Although PKI 166 attenuated the increase in GV as-
sociated with experimental diabetes, it had no effect on
the glomerular hyperfiltration that also accompanies ex-
perimental [38] and human diabetes [1]. This seemingly
discordant relationship between glomerular enlargement
and hyperfiltration is well documented in diabetes [2,
39] and while both are features of early diabetes, their
time courses are distinctly different [39]. Indeed, the find-
ing that glomerular enlargement precedes hyperfiltration
suggests that the increased GFR in early diabetes is not
the consequence of glomerular hypertrophy but may well
relate to other features of the diabetic state that induce
changes in feedback through the macula densa [40]. Fur-
thermore, in addition to its mitogenic effects, EGF also
increases preglomerular and postglomerular arteriolar
resistance which combined with a reduction in glomeru-
lar ultrafiltration coefficient (Kf) leads to a fall in GFR
[41]. Thus, it is also possible that blockade of the latter
effects with PKI 166 may have abrogated any fall in GFR
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that might have otherwise accompanied the reduction in
renal mass and GV observed in the present study.
Although EGFR kinase inhibition significantly re-
duced kidney enlargement in diabetes, complete normal-
ization was not achieved. This suggests that other factors
apart from the EGF-EGFR system are involved with the
mediation of kidney growth in diabetes. Indeed, a range
of other growth factor systems have not only been shown
to be increased in the diabetic kidney but also that specific
antagonism leads to a reduction in renal enlargement.
These include TGF-b [28], insulin-like growth factor-I
[42], and vascular endothelial growth factor [43]. Like the
present study, these others also demonstrate that while
several growth factors are up-regulated in early diabetes,
blockade of them all is not required to achieve an effect
on renal structure.
On the background of its known actions in both the
in vitro and in vivo settings [29], along with its overex-
pression in early diabetes [7], the present intervention
study provides the first information that inhibition of
EGFR tyrosine kinase phosphorylation attenuated kid-
ney growth, tubular cell proliferation, and glomerular hy-
pertrophy observed in early diabetes, while increasing
tubular apoptosis. These findings suggest a key role for
the EGF-EGFR pathway in the development of diabetes-
associated renal enlargement. However, while little is
known about their role in the kidney or in diabetes, it is
also possible that other members of the EGFR subfam-
ily, other EGFR agonists or growth-factor–independent
EGFR activating pathways may have contributed to the
findings of the present study. In particular, while PKI
166 is a potent inhibitor of EGFR, it also inhibits the
related orphan receptor, HER2 (ErbB2, neu) [44], impli-
cated in the pathogenesis of various malignancies. Fur-
ther, long-term studies will be required to determine
whether EGFR inhibition might ultimately lead to ame-
lioration of the disordered structure and dysfunction as-
sociated with progressive renal disease in diabetes.
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